Brief: Selecta Biosciences Reports First Quarter 2023 Financial Results
04/05/2023 12:51
May 4 (Reuters) - Selecta Biosciences Inc SELB.O :
* SELECTA BIOSCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES BUSINESS UPDATE
* SELECTA BIOSCIENCES INC - QTRLY LOSS PER SHARE $0.14
* SELECTA BIOSCIENCES INC - QTRLY COLLABORATION AND LICENSE
REVENUE $5.9 MILLION VERSUS $34 MILLION
Source text for Eikon: ID:nGNX1SlVqg
Further company coverage: SELB.O
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview